BACKGROUND: Intravenous thrombolysis with alteplase is the most effective therapy for acute ischemic stroke, but hemorrhagic transformation (HT) is a potentially dangerous complication of such thrombolysis. Few studies have investigated the predictors of HT after thrombolysis in Korean stroke patients. METHODS: From 2003 to 2009, acute ischemic stroke patients who received intravenous alteplase were included from the prospective stroke registry of Kyung Hee University Hospital. Patients submitted to CT or MRI scans with gradient echo sequences within 12-36 hours of thrombolysis. The Hemorrhage After Thrombolysis (HAT) score [ranging from 0 (minimum risk) to 5 (maximum risk)] was calculated retrospectively for each patient. The predictive ability of the HAT score for HT and symptomatic intracranial hemorrhage (sICH) was calculated using C statistics. RESULTS: Among 151 consecutive patients, HT was confirmed in 35 on follow-up brain imaging. Atrial fibrillation (OR=2.709, 95%CI=1.118-6.567) and low one-third CT scan (OR=3.419, 95%CI=1.281-9.121) increased the risk of HT after intravenous thrombolysis in multivariate logistic regression analysis. HT, sICH (based on the National Institute of Neurological Disorders and Stroke and the Safe Implementation of Treatment in Stroke-Monitoring Study definitions), unfavorable [modified Rankin Scale (mRS) score of 2-6] and poor (mRS score of 3-6) outcomes at 3 months, and mortality at 3 months were increased with higher HAT scores (C statistic=0.632, 0.637, 0.843, 0.670, 0.689, and 0.659, respectively; p=0.018, 0.036, 0.042, 0.002, 0.015, and <0.001). CONCLUSIONS: The HAT score can be used to predict the risk of sICH following intravenous thrombolysis and the long-term clinical outcome.
Atrial Fibrillation ; Follow-Up Studies ; Hemorrhage ; Humans ; Intracranial Hemorrhages ; Logistic Models ; Magnetic Resonance Imaging ; National Institute of Neurological Disorders and Stroke ; Neuroimaging ; Prospective Studies ; Retrospective Studies ; Stroke ; Thrombolytic Therapy ; Tissue Plasminogen Activator

BACKGROUND: Small proportions of all the elderly stroke patients receive recombinant tissue plasminogen activator (r-tPA) therapy, although old age is not a proven contraindication to intravenous thrombolytic therapy for acute ischemic stroke. The purpose of this study was to identify reasons for exclusion from r-tPA therapy and factors associated with the decision of r-tPA use in elderly patients with acute ischemic stroke. METHODS: From the acute stroke registries of 22 domestic university hospitals taking the r-tPA therapy from January 2007 to May 2010, we extracted data of all acute ischemic stroke patients who were aged 80 or over and arrived within onset 3 hours. For all patients, we assessed the eligibility of r-tPA therapy using National Institute of Neurological Disorders and Stroke (NINDS) r-tPA trial criteria. For eligible patients, we compared all clinical variables between patients who were treated with r-tPA and those who were not, and analyzed potential factors related to the decision of r-tPA use. RESULTS: A total of 494 patients were included in this study. 255 patients (51.6%) were excluded by NINDS r-tPA trial criteria and the major reasons for exclusion were minor neurological deficit (53.7%) and clinical improvement (17.3%). Among 239 patients who were eligible for r-tPA, 162 (32.8%) patients received r-tPA and 77 (15.6%) did not. Multivariable analysis showed that younger age, shorter time-delay from onset to admission, non-smoker, no history of prior stroke, good pre-stroke functional status and severe initial neurological deficit were independently associated with the decision of r-tPA use in the elderly stroke patients predictors for r-tPA treatment. CONCLUSION: In very elderly patients, mild neurological deficit on arrival and rapid clinical improvement in neurological symptoms were the main reasons for exclusion from thrombolytic therapy.
Aged ; Hospitals, University ; Humans ; National Institute of Neurological Disorders and Stroke ; Registries ; Stroke ; Thrombolytic Therapy ; Tissue Plasminogen Activator

BACKGROUND: The results of the National Institute of Neurological Disorders and Stroke (NINDS) r-tPA Stroke Trial generated considerable hope, but also concerns about whether their results could be replicated in clinical practice. We investigated whether r-tPA infusion could be administered in a community-based hospital, safely and effectively. METHODS: We analyzed, retrospectively, the data of 33 patients having suffered acute ischemic strokes and treated with intravenous r-tPA from February 2003 to December 2006. Safety was evaluated by intracranial hemorrhage, symptomatic intracranial hemorrhage, and mortality. Clinical neurological status was measured by National Institutes of Health Stroke Scale (NIHSS) at baseline, 24 hours, and 7 days after r-tPA treatment. Efficacy was assessed by the response rate of r-tPA using an improvement in the NIHSS by 4 or more points at 24 hours after treatment and the long-term out-come measured with the modified Rankin Scale (mRS) at 3 months after stroke. RESULTS: The median NIHSS was 18. Mean onset to needle time was 140+/-30 minutes. Of the 33 patients, 10 had intracranial hemorrhage and 2 had symptomatic intracranial hemorrhage. No deaths occurred. Fifteen patients showed improvement in their NIHSS by 4 or more points at 24 hours after r-tPA. On the mRS, 12 patients had a good outcome at 3 months. More specifically, 9 patients had no or minimal symptoms, 7 patients had mild to moderate disability, 10 patients had severe disability and 7 patients died. CONCLUSION: The safety andrd efficacy of administering intravenous r-tPA for acute ischemic stroke in a community-based hospital mirror the results of the NINDS stroke trial.
Humans ; Intracranial Hemorrhages ; National Institute of Neurological Disorders and Stroke ; National Institutes of Health (U.S.) ; Needles ; Retrospective Studies ; Stroke ; Tissue Plasminogen Activator

BACKGROUND: The results of the National Institute of Neurological Disorders and Stroke (NINDS) r-tPA Stroke Trial generated considerable hope, but also concerns about whether their results could be replicated in clinical practice. We investigated whether r-tPA infusion could be administered in a community-based hospital, safely and effectively. METHODS: We analyzed, retrospectively, the data of 33 patients having suffered acute ischemic strokes and treated with intravenous r-tPA from February 2003 to December 2006. Safety was evaluated by intracranial hemorrhage, symptomatic intracranial hemorrhage, and mortality. Clinical neurological status was measured by National Institutes of Health Stroke Scale (NIHSS) at baseline, 24 hours, and 7 days after r-tPA treatment. Efficacy was assessed by the response rate of r-tPA using an improvement in the NIHSS by 4 or more points at 24 hours after treatment and the long-term out-come measured with the modified Rankin Scale (mRS) at 3 months after stroke. RESULTS: The median NIHSS was 18. Mean onset to needle time was 140+/-30 minutes. Of the 33 patients, 10 had intracranial hemorrhage and 2 had symptomatic intracranial hemorrhage. No deaths occurred. Fifteen patients showed improvement in their NIHSS by 4 or more points at 24 hours after r-tPA. On the mRS, 12 patients had a good outcome at 3 months. More specifically, 9 patients had no or minimal symptoms, 7 patients had mild to moderate disability, 10 patients had severe disability and 7 patients died. CONCLUSION: The safety andrd efficacy of administering intravenous r-tPA for acute ischemic stroke in a community-based hospital mirror the results of the NINDS stroke trial.
Humans ; Intracranial Hemorrhages ; National Institute of Neurological Disorders and Stroke ; National Institutes of Health (U.S.) ; Needles ; Retrospective Studies ; Stroke ; Tissue Plasminogen Activator

INTRODUCTION: Intravenous administration of Recombinant Tissue Plasminogen Activator (IV-rTPA) has been an essential component of reperfusion treatment strategies in the aftermath of the 1995 National Institute of Neurological Disorders and Stroke (NINDS) TPA Stroke Study. However, it remains to be under-utilized both nationally and worldwide. Local data on thrombolytic use are very limited.

OBJECTIVES: This study aims to document our institution's experience with the use of intravenous thrombolysis in acute ischemic stroke cases by describing the demographic, clinical, radiographic, and management profiles of all our patients who were given IV - rTPA and their functional outcomes upon discharge and after three months.

METHOD: This is a descriptive study utilizing a clinical series design. Chart review of eighteen (18) patients who were admitted in our institution--a tertiary private hospital--due to acute ischemic stroke from January 2007 to August 2009 and who has given IV- rTPA was done. The patients' functional outcomes measured by the Modified Rankin Scale (MRS) upon discharge and at three months after stroke onset were documented by reviewing the patients' inpatient and outpatient records and by telephone interview conducted with the patients and/or their relatives.

RESULTS: The mean age of patients thrombolysed in our institution was 57.11 + 13.5 years (range: 31 to 80 years). All cases, except for one vertebrobasilar stroke, were anterior circulation strokes. Mean ictus-to-needle time frame for all thrombolysed patients was 174.3 + 56.6 minutes. The mean rTPA dose given to our patients was 0.87 + 0.08 mg/kg. A total 77.8% patients (14 of 18) received the standard rTPA dose of 0/9 mg/kg. Fourteen patients had follow-up imaging post-rTPA. Among these, 21.4% (3 of 14) developed non-symptomatic intracerebral hemorrhage (NSICH); 7.1% (1 of 14) developed a fatal symptomatic intracerebral hemorrhage (SICH). The mean baseline National Institutes of Health Stroke Scale (NIHSS) score of all patients was 14.9 + 5.9 (range: 4 to 24). Mean NIHSS score within the first 24 hours post-rTPA was 8.8 ± 6.1 (range: 0 to 19)--a 41% improvement from baseline. Eleven patients (11 of 18) or 61.1% were noted to have early improvement or an improvement of NIHSS score within the first 24 hours by ≥ 4. The mean follow-up NIHSS score beyond the first 24 hours post-rTPA was 5.5 ± 5.3 (range: 0 to 18), obtained at an average of 4.8 ± 2.4 days post-thrombolysis--a 63% improvement from the baseline mean NIHSS score. The mean MRS score of all patients upon hospital discharge was 3.17 ± 1.69. Two patients (2 of 18) or 11.1% expired 4 and 5 days post-thrombolysis; two (2 of 18) were lost to follow-up. For those who survived to discharge and not lost to follow-up (n=14), the mean MRS score at three months was noted to be 1.50 ± 1.09--a 53% improvement from mean MRS upon discharge. Seven of 18 patients (39%) had a favorable outcome defined as MRS ≤ 1 at three months post thrombolysis. Protocol deviations in our hospital were reported in 16.7% (3 of 18).

CONCLUSION: Our study showed trends to early improvement and favorable outcomes among stroke patients given IV-rTPA within 3 to 4.5 hours from ictus in our institution--with NIHSS scores improving by 40 to 60% during the course of their hospital stay, and 39% of patients having minimal or no disability at 3 months using the MRS. Our institution has more experience the standard rTPA dose of 0.9 mg/kg. A hospital brain rack team (BAT) that is on-call 24 hours' aids in the facilitation of thrombolytic treatment in acute ischemic strokes.

Human ; Aged 80 And Over ; Tissue Plasminogen Activator ; National Institute Of Neurological Disorders And Stroke (u.s.) ; Stroke ; Length Of Stay ; Brain Ischemia ; Inpatients ; Outpatients ; Follow-up Studies ; Lost To Follow-up ; Fibrinolytic Agents ; Cerebral Hemorrhage ; Reperfusion ; Administration, Intravenous ; Brain ; Hospitals, Private ; Demography ; Telephone

PURPOSE: In many other countries, based on research, recombinant tissue plasminogen activator (r-tPA) has been approved for the treatment of acute ischemic strokes. However, in Korea, little research has been done till now, in spite of using r-tPA widely. We sought to assess the feasibility and the efficacy of treatment and to evaluate the prognosis and complications at the violation of using r-tPA. Our study was compared with other previous studies. METHODS: A retrospective review is presented of 25 the cases of patients with acute ischemic stroke treated with rtPA according to the National Institutes of Neurological Disorders and Strokes (NINDS) protocol. We classified the groups by protocol violation (time, blood pressure, and computed tomography). We then analyzed neurologic outcomes by using the National Institutes of Health Strokes Scale (NIHSS) and complications based on whether or not intracerebral hemorrhage (ICH) had occurred. RESULTS: Of the 25 patients (mean age: 57 males: 19), 6 had time violation (onset time > 180 min), 4 had blood-pressure violation (systolic BP > 185 mmHg), 5 had CT violation (low density at initial CT). The NIHSS score improved in 64% of all patients after 24 hours. However, improvement was lower in the case of deviation present than it was in the case of deviation absent (time, blood pressure, and CT, respectively, 20%, 50%, and 40%; p-value respectively 0.0274, 0.8350, and 0.4125). ICH occurred in 6 cases, but in cases of deviation present, ICH occurred at a greater frequency. CONCLUSION: Our safety and feasibility of outcome compared favorably with NINDS and other previous studies. In addition, we confirmed that the presence of protocol deviation was associated a poor outcome.
Academies and Institutes ; Blood Pressure ; Cerebral Hemorrhage ; Humans ; Korea ; Male ; National Institute of Neurological Disorders and Stroke ; National Institutes of Health (U.S.) ; Nervous System Diseases ; Prognosis* ; Retrospective Studies ; Stroke* ; Thrombolytic Therapy ; Tissue Plasminogen Activator

BACKGROUND: Tissue plasminogen activator (tPA) is known to be effective if given within 3 hours after the onset of ischemic stroke. However, no study has been performed regarding what proportion of patients with acute ischemic stroke are actually given tPA within this time window. We therefore tried to figure out the performance rate of thrombolytic therapy and acute prognosis in hyperacute ischemic stroke patients. METHODS: We prospectively registered all the acute ischemic stroke patients. Thrombolyic therapy was decided strictly according to the NINDS tPA protocol and clinical monitoring was done by the NIH Stroke Scale (NIHSS). If tPA was not given, the reason was recorded. RESULTS: Among 613 acute stroke patients during a period of 2.5 years, there were 146 (23.8%) hyperacute ischemic stroke patients within 3 hours after onset. Even in the 29 cases of in-hospital stroke, the rate of early detection and management was only 27.6% (8 cases). Among the hyperacute stroke population, 56 (38.4%) patients were treated with the thrombolytic agent and 27 patients showed positive responses. Thrombolytic therapy was not tried in the remaining 90 patients. The most common reason was expectation of favorable outcome without thrombolysis. But among these patients, subsequent neurological worsening was noticed in 9 patients, particularly in those with vertebrobasilar stroke. CONCLUSIONS: Urgent notice and management of ischemic stroke needs to be more emphasized not only to the general public, but also to medical personnel. More close observation is especially needed in vertebrobasilar stroke cases (J Korean Neurol Assoc 19(5):447~451, 2001)
Humans ; National Institute of Neurological Disorders and Stroke ; Prognosis* ; Prospective Studies ; Stroke* ; Thrombolytic Therapy* ; Tissue Plasminogen Activator

BACKGROUND: Intravenous recombinant tissue plasminogen activator (r-tPA) infusion is the only established treatment for acute ischemic stroke so far. We explored whether the demonstrated efficacy of r-tPA could be applied to communi-ty-based hospitals in Korea and whether the immediate improvements after r-tPA infusion had any predicting value for long-term outcomes. METHODS:Twenty-six patients (mean age, 69; 46% female) with acute ischemic stroke were treated with r-tPA, abiding by the National Institute of Neurological Disorders and Stroke (NINDS) protocol. The Neurological status was measured with the National Institutes of Health Stroke Scale (NIHSS) at baseline, at 1 hour after r-tPA , at 24 hours, and at 7 days and the functional outcome was evaluated with the modified Rankin scale (mRS) and Barthel Index at 90 days after stroke. RESULTS: Of 26 patients, 16 (62%) made full recovery or became independent, 4 (15%) had severe physical disability, and 6 (23%) patients died. Three patients (11.5%) had intracranial hemorrhage (asymptomatic, 2; symptomatic, 1). There were no significant differences in age, sex, risk factors, baseline NIHSS scores, hemorrhagic complication, initial brain CT abnormalities, and onset to needle time between good (full recovery or mRS 0-2) and poor groups (mRS 3-5 or death) at day 90, except for the improvement of NIHSS examined at 1 hour after r-tPA (repeated measured ANOVA test, p<0.01). CONCLUSIONS The NINDS r-tPA protocol is feasible in the community-based hospitals in Korea with the safety and efficacy comparable to the results of NINDS r-tPA trials. In addition, we suggest that the immediate neurological improvement after r-tPA be a predictor for favorable long-term outcomes. (J Korean Neurol Assoc 19(4):364~369, 2001)
Brain ; Cerebral Infarction ; Humans ; Intracranial Hemorrhages ; Korea ; National Institute of Neurological Disorders and Stroke ; National Institutes of Health (U.S.) ; Needles ; Risk Factors ; Stroke* ; Thrombolytic Therapy ; Tissue Plasminogen Activator ; Treatment Outcome

BACKGROUND: Neuropsychological Differentiation between Alzheimer's disease and vascular dementia has been controversial. The aim of this study was to detect neuropsychological differences between Alzheimer's disease (AD) and vascular dementia (VD). METHODS: Twenty one patients who met the criteria for probable AD according to the National Institute of Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 22 patients who met criteria for probable VD according to the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN), were included in this study. These two dementia groups were matched for age, sex, education, Mini-Mental State Examination score, and severities of dementia. All patients underwent the Seoul Neuropsychological Screening Battery (SNSB). RESULTS: Patients with VD showed greater deficits in verbal fluency (P<.05) than AD patients. However, AD patients, compared with VD patients, showed greater deficits in verbal memory functions including the 3 words recall task. Otherwise, no significant between-group differences were found in task results. CONCLUSIONS: Neuropsychologically, patients with VD differ from patients with AD only in a few cognitive domains. (J Korean Neurol Assoc 19(2):143~148, 2001)
Alzheimer Disease* ; Dementia ; Dementia, Vascular* ; Education ; Humans ; Mass Screening ; Memory ; National Institute of Neurological Disorders and Stroke ; Neuropsychological Tests ; Neurosciences ; Seoul

BACKGROUND: Neuropsychological Differentiation between Alzheimer's disease and vascular dementia has been controversial. The aim of this study was to detect neuropsychological differences between Alzheimer's disease (AD) and vascular dementia (VD). METHODS: Twenty one patients who met the criteria for probable AD according to the National Institute of Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 22 patients who met criteria for probable VD according to the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN), were included in this study. These two dementia groups were matched for age, sex, education, Mini-Mental State Examination score, and severities of dementia. All patients underwent the Seoul Neuropsychological Screening Battery (SNSB). RESULTS: Patients with VD showed greater deficits in verbal fluency (P<.05) than AD patients. However, AD patients, compared with VD patients, showed greater deficits in verbal memory functions including the 3 words recall task. Otherwise, no significant between-group differences were found in task results. CONCLUSIONS: Neuropsychologically, patients with VD differ from patients with AD only in a few cognitive domains. (J Korean Neurol Assoc 19(2):143~148, 2001)
Alzheimer Disease* ; Dementia ; Dementia, Vascular* ; Education ; Humans ; Mass Screening ; Memory ; National Institute of Neurological Disorders and Stroke ; Neuropsychological Tests ; Neurosciences ; Seoul